Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

Karen A Cadoo, Ayca Gucalp, Tiffany A TrainaBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USAAbstract: Cellular proliferation, growth, and division following DNA (deoxyribonucleic acid) damage are tightly contro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cadoo KA, Gucalp A, Traina TA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/967a4806d15f4e5db66396534f057aa7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:967a4806d15f4e5db66396534f057aa7
record_format	dspace
spelling	oai:doaj.org-article:967a4806d15f4e5db66396534f057aa72021-12-02T03:33:02ZPalbociclib: an evidence-based review of its potential in the treatment of breast cancer1179-1314https://doaj.org/article/967a4806d15f4e5db66396534f057aa72014-08-01T00:00:00Zhttp://www.dovepress.com/palbociclib-an-evidence-based-review-of-its-potential-in-the-treatment-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Karen A Cadoo, Ayca Gucalp, Tiffany A TrainaBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USAAbstract: Cellular proliferation, growth, and division following DNA (deoxyribonucleic acid) damage are tightly controlled by the cell-cycle regulatory machinery. This machinery includes cyclin-dependent kinases (CDKs) which complex with their cyclin partners, allowing the cell cycle to progress. The cell-cycle regulatory process plays a critical role in oncogenesis and in the development of therapeutic resistance; it is frequently disrupted in breast cancer, providing a rational target for therapeutic development. Palbociclib is a potent and selective inhibitor of CDK4 and -6 with significant activity in breast cancer models. Furthermore, it has been shown to significantly prolong progression-free survival when combined with letrozole in the management of estrogen receptor-positive metastatic breast cancer. In this article we review the cell cycle and its regulatory processes, their role in breast cancer, and the rationale for CDK inhibition in this disease. We describe the preclinical and clinical data relating to the activity of palbociclib in breast cancer and the plans for the future development of this agent.Keywords: cell-cycle regulation, cyclin-dependent kinases, CDK4/6 inhibitionCadoo KAGucalp ATraina TADove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 123-133 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cadoo KA Gucalp A Traina TA Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
description	Karen A Cadoo, Ayca Gucalp, Tiffany A TrainaBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USAAbstract: Cellular proliferation, growth, and division following DNA (deoxyribonucleic acid) damage are tightly controlled by the cell-cycle regulatory machinery. This machinery includes cyclin-dependent kinases (CDKs) which complex with their cyclin partners, allowing the cell cycle to progress. The cell-cycle regulatory process plays a critical role in oncogenesis and in the development of therapeutic resistance; it is frequently disrupted in breast cancer, providing a rational target for therapeutic development. Palbociclib is a potent and selective inhibitor of CDK4 and -6 with significant activity in breast cancer models. Furthermore, it has been shown to significantly prolong progression-free survival when combined with letrozole in the management of estrogen receptor-positive metastatic breast cancer. In this article we review the cell cycle and its regulatory processes, their role in breast cancer, and the rationale for CDK inhibition in this disease. We describe the preclinical and clinical data relating to the activity of palbociclib in breast cancer and the plans for the future development of this agent.Keywords: cell-cycle regulation, cyclin-dependent kinases, CDK4/6 inhibition
format	article
author	Cadoo KA Gucalp A Traina TA
author_facet	Cadoo KA Gucalp A Traina TA
author_sort	Cadoo KA
title	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
title_short	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
title_full	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
title_fullStr	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
title_full_unstemmed	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
title_sort	palbociclib: an evidence-based review of its potential in the treatment of breast cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/967a4806d15f4e5db66396534f057aa7
work_keys_str_mv	AT cadooka palbociclibanevidencebasedreviewofitspotentialinthetreatmentofbreastcancer AT gucalpa palbociclibanevidencebasedreviewofitspotentialinthetreatmentofbreastcancer AT trainata palbociclibanevidencebasedreviewofitspotentialinthetreatmentofbreastcancer
_version_	1718401745649926144

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

Ejemplares similares